If you’ve spent any time reading about research peptides, you’ve probably seen a number like this:
Purity: 99%+
It sounds straightforward.
If something is 99% pure, then 99% of the material must be the peptide and 1% must be something else, right?
Not necessarily.
In peptide testing, “99% purity” usually refers to the result of a specific analytical test, most often high-performance liquid chromatography, or HPLC. It does not automatically mean that 99% of everything physically sitting in a vial is peptide by weight.
That distinction may sound technical, but it’s one of the most useful things a newcomer can learn about peptide quality.
“Purity” Needs a Measurement Behind It
The first question to ask whenever you see a purity claim is:
Pure according to what test?
For synthetic peptides, HPLC is one of the most widely used analytical tools for assessing peptide-related impurities. A recent review of peptide drug quality found that reversed-phase HPLC remains a standard approach for purity testing, while mass spectrometry and other methods are commonly used alongside it for identification and deeper characterization.
So when a peptide supplier says:
99.4% purity by HPLC
that is much more informative than simply saying:
99.4% pure.
The first statement tells you how the number was obtained.
What Does HPLC Do?
HPLC separates different components in a sample.
A simplified way to picture the process is to imagine dropping several kinds of runners onto a race course.
Some move through quickly.
Others interact more strongly with the course and move more slowly.
They eventually reach the finish line at different times.
HPLC does something similar with molecules.
A peptide sample is carried through a chromatography column. Different compounds interact with the column differently and therefore emerge at different times.
A detector records what comes out.
The resulting graph is called a chromatogram.
What Are the Peaks on an HPLC Chromatogram?
A chromatogram usually contains peaks.
The major peptide may produce one large peak.
Other compounds may produce smaller peaks.
For example, a simplified chromatogram might show:
- Main peptide: 99.2%
- Minor component A: 0.4%
- Minor component B: 0.3%
- Minor component C: 0.1%
That could lead to a reported chromatographic purity of about 99.2%.
The number generally comes from the relative integrated area of the detected peaks under the test conditions.
It tells you that the major detected chromatographic component dominates the sample.
That’s useful information.
But it still doesn’t answer every question about the vial.
99% HPLC Purity Does Not Mean 99% of the Powder by Weight
This is the part that surprises many people.
A dry peptide sample may contain things that aren’t measured as peptide-related peaks in the same way.
Depending on how the material was made and prepared, a sample can also contain:
- residual water
- counterions
- salts
- residual solvents
- formulation components.
So a peptide might have 99% chromatographic purity while its total physical mass includes additional non-peptide material.
Modern peptide quality standards therefore distinguish among things such as identity, purity, assay or peptide content, and impurities rather than treating them as one measurement.
A useful rule is:
HPLC purity is not automatically the same thing as peptide content by weight.
What Are Counterions?
Counterions are another reason vial weight and chromatographic purity can differ.
Many peptides carry electrical charges.
To produce an electrically neutral salt, oppositely charged ions may be present.
Common peptide counterions include compounds such as:
- trifluoroacetate, often abbreviated TFA
- acetate.
These counterions can contribute to the total dry mass of a peptide preparation.
Yet they are not necessarily represented as peptide impurity peaks in the same way as truncated or altered peptide sequences.
So if someone sees:
10 mg material
and
99% HPLC purity
it is too simplistic to conclude:
Therefore exactly 9.9 mg must be active peptide molecules.
More information may be needed to make that quantitative statement.
Purity and Identity Are Different Questions
There’s another important issue.
Imagine you test a sample by HPLC and find one giant peak accounting for 99.8% of the detected chromatographic area.
That tells you the sample is dominated by one component.
But what if that component is the wrong peptide?
The HPLC purity number alone would not necessarily catch that problem.
This is why laboratories often use mass spectrometry in addition to chromatography.
FDA research into peptide quality has specifically emphasized the value of combining chromatographic separation with mass-spectrometric methods to characterize peptide active ingredients and peptide-related impurities.
What Does Mass Spectrometry Tell You?
Mass spectrometry measures molecules based on their mass-to-charge ratio.
For a peptide, researchers can calculate what molecular mass the intended sequence should have.
They can then compare that expected value with what the instrument observes.
If the measured data are consistent with the expected mass, that provides evidence supporting the identity of the peptide.
So, in simplified form:
HPLC asks:
How chromatographically clean does this sample appear?
Mass spectrometry asks:
Does the molecular mass support the expected identity?
Those are different questions.
That is why seeing both on a Certificate of Analysis can be more useful than seeing either one alone.
Even Mass Spectrometry Doesn’t Answer Everything
Mass spectrometry is powerful, but it is not magic.
The correct molecular mass does not automatically establish:
- exact purity
- exact peptide content
- sterility
- bacterial endotoxin levels
- absence of every possible contaminant
- biological activity
- suitability for human use.
Scientists use different tests for different properties.
The 2026 review of peptide quality assessment notes that peptide identity can be supported using multiple orthogonal methods, including HPLC, mass spectrometry, amino-acid analysis, tandem MS, peptide mapping, NMR, and biological assays depending on the application.
“Orthogonal” is just a technical way of saying the methods approach the question from different directions.
What Is a Certificate of Analysis?
This is where a Certificate of Analysis, or COA, becomes useful.
A peptide COA may include information such as:
- peptide or compound name
- lot number
- HPLC result
- expected molecular mass
- observed molecular mass
- testing date
- analytical laboratory
- chromatogram
- mass spectrum.
The exact contents vary.
A COA is most useful when it is connected to a specific production batch.
Why the Lot Number Matters
Imagine a peptide supplier receives one batch in January and another in August.
The chemical name may be identical.
But the two batches were produced separately.
The January test results therefore do not automatically describe the August material.
That is why researchers care about lot-specific testing.
The ideal chain looks like:
Product → Lot Number → Analytical Report
For example, someone evaluating a retatrutide research peptide for laboratory work would ideally look at the HPLC and mass-spectrometry information tied to the actual lot being supplied rather than relying on one generic purity number used indefinitely.
Retatrutide is an investigational molecule, so laboratory research material should also be distinguished from the investigational pharmaceutical formulations used in clinical trials.
What Kinds of Peptide Impurities Can Exist?
Peptide synthesis happens step by step.
That creates several opportunities for related molecules to appear.
Possible peptide-related impurities can include:
- shorter sequences
- deletion sequences
- incompletely modified peptides
- oxidation products
- degradation products
- altered amino-acid forms.
This is one reason peptide analysis can become surprisingly complicated.
FDA research has used high-resolution LC-MS/MS methods to identify peptide-related impurities that may be difficult to fully characterize using conventional HPLC-UV alone.
The cleaner the chromatogram, the fewer significant detectable chromatographic impurities there may be.
But “clean chromatogram” still doesn’t mean “every possible quality question has been answered.”
Why Does This Matter for Research?
If you’re just curious about peptides, the difference between 98.9% and 99.3% may sound trivial.
In some experiments, it may be.
In others, impurities can matter a great deal.
Imagine a receptor assay where a peptide-related impurity still has some biological activity.
Or a stability experiment where degradation products grow over time.
Or an analytical method being developed specifically to detect small changes in molecular composition.
If researchers don’t know what material they started with, interpreting the results becomes harder.
That is why analytical characterization is part of good experimental design.
Does Higher Purity Always Mean Better?
Not necessarily in every research situation.
A higher purity specification usually requires more purification.
That can increase:
- cost
- production complexity
- time
- loss of material during purification.
Some early screening experiments may not require the same purity level as highly sensitive biochemical work.
The appropriate specification depends on the experiment.
This is another reason a single purity percentage should not be treated as a universal quality score.
What Should a Layperson Look For?
You don’t need to become a chromatography expert to evaluate a peptide-testing claim more intelligently.
A few simple questions help.
Does the supplier say how purity was measured?
“99% by HPLC” is more useful than “ultra pure.”
Is identity tested separately?
Mass spectrometry or another appropriate identity method provides information HPLC purity alone does not.
Is the testing lot-specific?
The report should ideally match the batch being supplied.
Can you see the underlying report?
An actual chromatogram or analytical report provides more context than a badge saying “third-party tested.”
Are the claims limited to what the test actually shows?
A company should not use HPLC purity as proof of sterility, clinical safety, or pharmaceutical approval.
Does 99% Purity Mean a Peptide Is Safe?
No.
This is probably the most important takeaway.
Analytical purity and safety are different concepts.
A chemical can be extremely pure and still be toxic.
Another compound can be safe for an intended use at one dose and harmful under different conditions.
Clinical safety requires much more than chemical purity.
For approved peptide medicines, regulators evaluate extensive information about manufacturing, formulation, stability, toxicology, clinical effectiveness, and adverse events.
A research peptide COA is not a substitute for that process.
Why “Third-Party Tested” Is Only the Beginning
Independent testing can be useful.
Having an outside laboratory perform the analysis separates the analytical result from the company selling the material.
But even then, researchers should ask:
What was tested?
Which method was used?
Which lot was tested?
What did the result actually show?
The phrase “third-party tested” sounds reassuring, but the report is where the scientific information actually lives.
Conclusion
“99% pure” sounds like a complete description.
It isn’t.
For peptides, the number usually refers to a particular analytical measurement, often chromatographic purity determined by HPLC.
That tells researchers something important about the sample.
But it does not automatically tell them:
- exactly how much peptide is present by total weight
- whether the major component is definitely the correct molecule
- whether the material is sterile
- whether it is safe
- whether it is suitable for medical use.
That’s why peptide characterization often combines several pieces of evidence.
HPLC can help describe purity.
Mass spectrometry can help support identity.
Lot-specific documentation connects the tests to the material being studied.
Once you understand those three ideas, a label saying “99% purity” becomes much more meaningful.
References
U.S. Food and Drug Administration. Regulatory Science Research on Complex Mixtures and Peptides. FDA describes the use of HPLC, LC-MS, and LC-MS/MS for peptide characterization and impurity profiling. FDA peptide analytical research
Regulatory and Analytical Considerations for the Quality Assessment of Peptide Drugs. Journal of Pharmaceutical Investigation. 2026. Covers HPLC, mass spectrometry, assay, identity, and peptide-related impurities. Peptide quality assessment review